menu ☰
menu ˟

FDA approves Addyi to treat hypoactive sexual desire in premenopause

19 Aug 2015
The FDA approved Addyi to treat hypoactive sexual desire in premenopausal women, making it the first FDA-approved drug to treat sexual desire disorders in either men or women.The non-hormonal, once-daily drug Addyi (flibanserin, Sprout Pharmaceutical...

Click here to view the full article which appeared in Psychiatry

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.